ILMN
ILLUMINA, INC.
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$208.21
+0.85%Price chart
Aug 13Aug 18Aug 21Aug 26Aug 31Sep 3Sep 9Sep 14
Key dataSep 14, 2026
Open$206.74
From 52W high−8.56%
Volume1.98M
Market cap$31.44B
P/E (TTM)38.5x
P/S (TTM)7.0x
Div yield—
Key dataSep 14, 2026
Open
$206.74
From 52W high
−8.56%
Volume
1.98M
Market cap
$31.44B
ValuationView details →
P/E (Fwd)
36.5x
EV/EBITDA
24.1x
P/E (TTM)
38.5x
RSI (14)
50.5
MomentumView details →
1D Return
+0.85%
YTD Return
+58.31%
SummaryUpdated Jun 1, 2026
Illumina, Inc. (NASDAQ:ILMN) is a leading biotechnology company founded in 1998 and based in San Diego, California, that went public in 2000. The company pioneered the development of DNA sequencing and array-based solutions that have revolutionized genetic and genomic analysis. Over its 25+ year history, Illumina has established itself as the dominant player in the DNA sequencing market, providing the foundational technology that enables genomic research, clinical diagnostics, and personalized medicine applications worldwide.
Similar companies
Latest newsMore news →
Bloom Energy, Illumina, and Everpure are set to be added to the S&P 500 index.11d agoBiondo Investment Advisors LLC acquired a new minority stake in Illumina, Inc. by purchasing 10,630 shares valued at approximately $1.87 million, as disclosed in a 13F filing.22d agoAllworth Financial LP acquired a new position in Illumina, Inc. by purchasing 5,976 shares valued at approximately $1,051,000 in the second quarter, as disclosed in its 13F filing.23d ago